Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05093374 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 25, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Oct 1, 2023 to Dec 31, 2025 Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  2. Primary and study completion dates: Oct 1, 2022 to Oct 1, 2023v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).
Trial Details
NCT Number NCT05093374
Lead Sponsor Medical University of Vienna
Conditions Exudative Macular Degeneration
Enrollment 290 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov